Trial Profile
A Phase II, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Clinical Validity and Safety of IOP Injection for Magnetic Resonance Imaging (MRI) Contrast Agent in Hepatocellular Carcinoma (HCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Nov 2020
Price :
$35
*
At a glance
- Drugs Iron oxide-PEG (Primary)
- Indications Liver cancer
- Focus Diagnostic use
- Sponsors Megapro Biomedical Company
- 24 Nov 2020 Status changed from recruiting to completed.
- 19 Feb 2020 Planned End Date changed from 1 Jul 2020 to 1 Oct 2020.
- 19 Feb 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jul 2020.